Evaluation of the CONVIVO System
Glioblastoma, Glial Tumor, Brain Metastases
About this trial
This is an interventional diagnostic trial for Glioblastoma
Eligibility Criteria
Inclusion Criteria:
- Adult patients (age>18)
- Adults presenting with suspected intracranial gliomas (including glioblastoma), cerebral metastasis, meningiomas, acoustic neuromas, and pituitary adenomas, who are surgical candidates
- Adults able to provide informed consent.
Exclusion Criteria:
- Pregnancy
- Children (age <18 years)
- Fluorescein sodium (FNa) allergy
Sites / Locations
- Dartmouth-Hitchcock Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
CONVIVO system
Conventional histologic evaluation
During tumor resection, study investigators trained in the use of the system will determine when the CONVIVO imaging system will be used for in vivo¬ imaging. At this point 5 mg/kg of fluorescein will be administered intravenously by an anesthesia provider over one minute.Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique.
Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.